Protagonist Therapeutics, Inc. — Q3 2023 Form 10-Q Summary
Business context and reporting period
Protagonist is a clinical-stage biopharmaceutical company developing peptide-based therapies for hematology, blood disorders, inflammatory diseases and immunomodulatory conditions. Key programs are wholly owned rusfertide (PTG-300) and partnered JNJ-2113 (formerly PN-235). The company operates as one segment. This unaudited Form 10-Q covers the three and nine months ended September 30, 2023, filed November 2, 2023.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| License and collaboration revenue | $0 | $0 | $0 | $26.6 million |
| Research and development expense | $30.7 million | $25.4 million | $91.3 million | $96.3 million |
| General and administrative expense | $7.7 million | $6.9 million | $25.4 million | $25.1 million |
| Total operating expenses | $38.3 million | $32.3 million | $116.7 million | $121.4 million |
| Net loss | $34.1 million | $31.2 million | $106.3 million | $93.2 million |
| Net loss per share | $0.58 | $0.64 | $1.91 | $1.90 |
There was no revenue in Q3 2023 and no operating margin is meaningful because the company has no product sales and no current collaboration revenue. Operating loss was $38.3 million in Q3 and $116.7 million for the first nine months. Interest income increased to $4.3 million in Q3 and $10.7 million for the first nine months, benefiting from higher invested balances and yields.
- Cash, cash equivalents and marketable securities were $322.7 million at September 30, 2023, compared with $237.4 million at December 31, 2022.
- Cash used in operating activities was $87.2 million for the first nine months, versus $76.5 million in the prior-year period.
- Investing activities provided $22.0 million, primarily from maturities of marketable securities.
- Financing activities provided $170.0 million, including $107.8 million from an April public offering, $24.3 million from the ATM facility and approximately $34.4 million from warrant-related transactions.
- Cash, cash equivalents and restricted cash increased to $230.8 million from $153.0 million at September 30, 2022.
- The filing does not disclose material debt or borrowings; liabilities primarily consist of operating lease liabilities, accounts payable and accrued expenses.
- Accumulated deficit was $643.0 million, and total stockholders’ equity was $302.1 million at September 30, 2023.
Material changes versus the prior comparable period
- Nine-month collaboration revenue fell $26.6 million to zero because the Janssen performance obligation was completed as of June 30, 2022. The prior-year period included a $25.0 million JNJ-2113 milestone.
- Q3 research and development expense increased 21% to $30.7 million, primarily due to a $9.1 million increase in rusfertide clinical and contract manufacturing costs for the Phase 3 VERIFY trial. This was partly offset by a $4.0 million reduction in PN-943 spending.
- For the first nine months, research and development expense decreased 5% because PN-943 spending declined $32.2 million and preclinical and discovery spending declined $3.0 million, partly offset by a $31.0 million increase in rusfertide spending.
- PN-943 development was de-prioritized, and the company does not intend to dedicate further internal resources to its clinical development or contract manufacturing activities.
- Net loss increased 9% in Q3 and 14% for the first nine months, despite higher interest income, primarily reflecting the absence of collaboration revenue and increased operating losses.
- Shares outstanding increased to 57.6 million at September 30, 2023 from 49.3 million at December 31, 2022, reflecting equity offerings and other equity issuances.
Guidance, outlook, commentary and risks
- Management expects fourth-quarter 2023 research and development expense to remain relatively flat compared with the first nine months of 2023 and expects cash burn to approximate current levels for the remainder of 2023.
- Cash burn is expected to increase in 2024 as the company advances rusfertide into later-stage development and prepares for potential commercialization.
- Management believes existing cash, cash equivalents and marketable securities will fund anticipated requirements for at least the next 12 months, but expects to raise substantial additional capital to advance rusfertide and other programs.
- Rusfertide’s Phase 3 VERIFY trial was ongoing, with enrollment completion expected in the first quarter of 2024. The company reported positive topline results from the REVIVE Phase 2 randomized-withdrawal portion and completed the PACIFIC Phase 2 trial during the second quarter of 2023.
- Janssen reported positive Phase 2b FRONTIER1 results for JNJ-2113 and initiated Phase 3 psoriasis studies and a Phase 2b ulcerative colitis study. A $50.0 million milestone was earned after quarter-end when the third patient was dosed in the ICONIC-TOTAL Phase 3 trial; the filing also describes the milestone as associated with ICONIC-LEAD in late October, so investors should verify the precise study designation in subsequent disclosures.
- The company remains eligible for additional Janssen development and regulatory milestones and tiered royalties of 6% to 10% on net product sales, but timing and receipt are contingent on development, regulatory and commercial success.
- Principal risks include clinical-trial failure or delay, patient enrollment and manufacturing constraints, adverse safety findings, regulatory uncertainty, reliance on Janssen and third-party manufacturers and CROs, need for additional financing and potential equity dilution.
- Management identified macroeconomic, inflation, geopolitical, supply-chain and banking-system risks. The company states that inflation has not materially affected results to date but could increase future clinical, manufacturing and operating costs.
- Disclosure controls and procedures were deemed effective at the reasonable-assurance level, with no material changes in internal control over financial reporting reported during the quarter. No material legal proceedings were disclosed.
Important facts for investors to verify
- Enrollment progress, timelines, safety data and regulatory interactions for the rusfertide VERIFY Phase 3 trial.
- The exact Janssen milestone-triggering trial and the timing of the $50.0 million payment recognized after September 30, 2023.
- Projected 2024 cash burn, financing needs and the duration of the stated cash runway.
- Future development, regulatory and commercial milestones for JNJ-2113 and the probability and timing of related payments.
- Potential dilution from the 2.7 million outstanding pre-funded warrants, employee equity awards, the ATM facility and future capital raises.
- Safety findings and regulatory requirements arising from prior rusfertide clinical holds and the company’s broader dependence on successful clinical and regulatory outcomes.